Anti-arenaviral compounds
View Patent ↗Described herein are 4-methyl-piperazine-1-carbothioic acid amide derivatives and analogs, as well as compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by hemorrhagic fever viruses, such as Arenaviruses.
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound selected from the group consisting of 4-methyl-piperazine-1-carbothioic acid (3,4-dichloro-phenyl)-amide and 4-ethyl-piperazine-1-carbothioic acid (3,4-dichloro-phenyl)-amide, wherein said pharmaceutical composition is suitable for administration in a human or animal, wherein said administration is selected from the group consisting of: oral administration, rectal administration, parenteral administration, intravaginal administration, intraperitoneal administration and administration by inhalation.
2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound selected from the group consisting of 4-methyl-piperazine-1-carbothioic acid (3,4-dichloro-phenyl)-amide and 4-ethyl-piperazine-1-carbothioic acid (3,4-dichloro-phenyl)-amide and an additional antiviral agent selected from the group consisting of zidovudine, acyclovir, ganciclovir, vidarabidine, idoxuridine, trifluridine, foscarnet, interferon, amantadine, rimantadine, and ribavirin, wherein said pharmaceutical composition is suitable for administration in a human or animal, wherein said administration is selected from the group consisting of: oral administration, rectal administration, parenteral administration, intravaginal administration, intraperitoneal administration and administration by inhalation.
3. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of 4-methyl-piperazine-1-carbothioic acid (3,4-dichloro-phenyl)-amide, wherein said pharmaceutical composition is suitable for administration in a human or animal, wherein said administration is selected from the group consisting of: oral administration, rectal administration, parenteral administration, intravaginal administration, intraperitoneal administration and administration by inhalation.
4. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of 4-ethyl-piperazine-1-carbothioic acid (3,4-dichloro-phenyl)-amide, wherein said pharmaceutical composition is suitable for administration in a human or animal, wherein said administration is selected from the group consisting of: oral administration, rectal administration, parenteral administration, intravaginal administration, intraperitoneal administration and administration by inhalation.
5. The pharmaceutical composition of claim 1 , wherein said pharmaceutically acceptable carrier is selected form the group consisting of solvents, diluents, dispersion aids, suspension aids, surface active agents, isotonic agents, thickening agents, emulsifying agents, preservatives, solid binders and lubricants.
6. The pharmaceutical composition of 1 , wherein said pharmaceutically acceptable carrier is solid.
7. The pharmaceutical composition of 1 , wherein said pharmaceutically acceptable carrier is liquid.
8. The pharmaceutical composition of claim 1 , wherein said parenteral administration is selected from the group consisting of: intramuscular injection, subcutaneous injection and intravenous infusion.